Navigation Links
Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth
Date:4/26/2012

oes not include the up-front payments in respect of in-licensed and acquired products made in Q1 2012.
  • Net debt at March 31, 2012 was $214 million (December 31, 2011: $468 million), a reduction of $254 million, principally due to the strong free cash flow generated in Q1 2012.

  • 2012 OUTLOOK


    Having made a strong start to the year, we reiterate our confidence in good earnings growth for 2012, while investing in our business to support sustained future growth.

    For the full year we now expect product sales growth in the mid teens range. Combining this with lower royalties and other revenues, which are expected to be 15% to 25% lower year on year, we are forecasting revenue growth in the low teens range.

    We anticipate the marginal dilution in gross margins seen this quarter will continue, reflecting the full year impact of our acquisition of ABH.

    We will continue to advance our promising pipeline of early and late stage programs, and we will be investing in our recent pipeline acquisitions and in the treatment of binge eating disorder, following recent positive data. The rate of increase in operating costs seen in the first quarter will not continue through the full year, but as we invest in our pipeline, continue to expand our international commercial activities and absorb a full year of ABH's operating costs, we now expect combined Non GAAP R&D and SG&A spending to increase by 12% to 14% compared to 2011.

    We expect our tax rate for 2012 to be in the range of 20% to 22%.

    FIRST QUARTER 2012 AND RECENT PRODUCT AND PIPELINE DEVELOPMENTS


    Products


    VPRIV manufacturing update

    • On February 22, 2012 Shire announced that the European Medicines Agency's ("EMA") Committee for Medicinal Products for Human Use had approved the production of VPRIV in its new biologics manufacturing facility in Lexington, Massachusetts and this decision
      '/>"/>

    SOURCE Shire plc
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

    Related medicine technology :

    1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
    2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
    3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
    4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
    5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
    6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
    7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
    8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
    9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
    10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
    11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... , Dec. 24, 2014  Actavis plc (NYSE: ... Company has received a complete response letter from ... its New Drug Application (NDA) for the fixed-dose ... treatment of hypertension.   Photo - ... disappointed in the receipt of a complete response ...
    (Date:12/24/2014)... , Dec. 24, 2014 Kinex Pharmaceuticals announced ... KX2-361 at Roswell Park Cancer Institute. KX2-361 ... drug that has shown potent inhibitory activity against a ... that are resistant to Temozolomide (T98G), the most widely ... a well-established brain tumor mouse model, KX2-361 consistently clears ...
    (Date:12/24/2014)... 2014  Conkwest, Inc., the Natural Killer Cell ... Killer (NK) cell-line platform, Neukoplast® (NK-92™) as an ... , NantWorks founder, physician scientist and biotechnology entrepreneur, ... approximately $48 million of the Company,s Class A ... will be named Co-Chairman of the Conkwest Board ...
    Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5
    (Date:12/26/2014)... (PRWEB) December 26, 2014 It is said ... great dress. Today, UWDress.com, the famous wedding dress supplier, ... launches a site-wide cocktail gown promotion. , UWDress.com’s navy ... collection, and they come in high fashion styles. Simple dresses ... depending on the occasion; they are specially designed for those ...
    (Date:12/26/2014)... December 26, 2014 “Many people become ... personal injury claim issues and phone calls with insurance ... an article featuring their free eBook on pedestrian ... eBook on pedestrian and bicycle auto accident claims assures ... fully capable of professionally handling their case while they ...
    (Date:12/25/2014)... The microscopy market is estimated to grow ... million by 2019. Optical microscopy is the largest ... product segment is expected to show the fastest ... on nanotechnology, technological advancements, and increasing federal support ... Get Full Copy of Report @ http://www.marketsandmarkets.com/Market-Reports/world-microscopy-399.html ...
    (Date:12/25/2014)... York, New York (PRWEB) December 25, 2014 ... the 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) ... LLP reports. According to an Order issued in the ... 20th, the Court will convene an open conference on ... Building and United States Courthouse in West Palm Beach, ...
    (Date:12/25/2014)... Recently, BellasDress has launched its Christmas ... BellasDress has chosen their best-selling lace wedding dresses, vintage ... holiday season. , Now, BellasDress.com features popular women’s ... at discount prices. The business hopes everyone can have ... , “All our elegant products are made with ...
    Breaking Medicine News(10 mins):Health News:UWDress.com Shows Its New Navy Cocktail Dresses For 2015 2Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2
    ... million Americans, OptumHealth developed myOptumHealth.com to provide individuals seeking health ... easy-to-understand and actionable content, tools and resources. , ... ... -- OptumHealth Inc., the health and wellness business of UnitedHealth ...
    ... Medical Record and practice billing solutions for the healthcare industry, is ... Chief Commercial Officer. Flormann brings 25 years of experience in ... market development to Glenwood Systems. , ... Waterbury, CT ...
    ... University of Utah researchers have developed an automobile ignition ... sending text messages while driving. , The university has obtained ... a private company that hopes to see it on the ... $50 per key plus a yet-undetermined monthly service fee. ...
    ... Calif., Dec. 10 PADRES Contra El Cancer, an,organization ... children,with cancer and their families, will host its Annual ... 13, 2008. , ... afternoon playing,and sledding amongst 40 tons of snow while ...
    ... Walter Reed Soldiers Visit Atlantic City , , ... of a soldier who had been wounded in the Iraq conflict and ... the invitation for a visit to Harrah,s Resorts in Atlantic City. , ... young servicemen and women, recovering , from war injuries and ...
    ... (NYSE: VAR ) announced today that it will report ... of regular trading on Thursday, January 29, 2009. The news ... parties at 2:00 p.m. PT. , , ... January 29, 2009. The news release and information on the conference ...
    Cached Medicine News:Health News:OptumHealth Launched myOptumHealth.com, Health and Wellness Information Destination with Clinically Reviewed Content, Tools and Resources 2Health News:OptumHealth Launched myOptumHealth.com, Health and Wellness Information Destination with Clinically Reviewed Content, Tools and Resources 3Health News:OptumHealth Launched myOptumHealth.com, Health and Wellness Information Destination with Clinically Reviewed Content, Tools and Resources 4Health News:OptumHealth Launched myOptumHealth.com, Health and Wellness Information Destination with Clinically Reviewed Content, Tools and Resources 5Health News:Glenwood Systems, LLC Appoints Ron Flormann Chief Commercial Officer 2Health News:Car key jams teen drivers' cell phones 2Health News:Car key jams teen drivers' cell phones 3Health News:Car key jams teen drivers' cell phones 4Health News:PADRES Contra El Cancer to Host its 10th Annual Posada Holiday Celebration for Children with Cancer 2Health News:Wounded Warriors to be Holiday Guests of Harrah's Entertainment 2Health News:Varian Medical Systems Schedules First Quarter FY2009 News Release and Conference Call 2Health News:Varian Medical Systems Schedules First Quarter FY2009 News Release and Conference Call 3
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    Medicine Products: